The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
== Further reading == Moses HL, Roberts AB, Derynck R (July 2016). "The Discovery and Early Days of TGF-β: A Historical Perspective". Cold Spring Harbor Perspectives in Biology. 8 (7) a021865. doi:10.1101/cshperspect.a021865. PMC 4930926. PMID 27328871.
Plag, Ingo "Word-Formation in English", Cambridge University Press, 2003, ISBN à0521525632, 9780521525633 Rider, Nic G.; Caso, Taymy J.; Czech, Spencer; Karasic, Dan H. (2022). "Terminology in Transgender Medicine". In van Trotsenburg, Mick; Luikenaar, Rixt A. C.; Meriggiola, Maria Cristina (eds.). Context, Principles and Practice of TransGynecology: Managing Transgender Patients in ObGyn Practice. Cambridge UP. doi:10.1017/9781108899987. ISBN 978-1-108-89998-7. Ragosta, Sachiko; Obedin-Maliver, Juno; Fix, Laura; Stoeffler, Ari; Hastings, Jen; Capriotti, Matthew R.; Flentje, Annesa; Lubensky, Micah E.; Lunn, Mitchell R.; Moseson, Heidi (1 September 2021). "From 'Shark-Week' to 'Mangina': An Analysis of Words Used by People of Marginalized Sexual Orientations and/or Gender Identities to Replace Common Sexual and Reproductive Health Terms". Health Equity. 5 (1). Mary Ann Liebert: 707–717. doi:10.1089/heq.2021.0022. PMC 8665782. PMID 34909540. This article incorporates text from this free content work. Licensed under CC-BY 4.0. Rajalingam R (2012). "Overview of the Killer Cell Immunoglobulin-Like Receptor System". Immunogenetics. Methods in Molecular Biology. Vol. 882. pp. 391–414. doi:10.1007/978-1-61779-842-9_23. ISBN 978-1-61779-841-2. PMID 22665247. Saladin, Kenneth S. (2010). Anatomy & Physiology The Unity of Form and Function (5th ed.). McGraw Hill. ISBN 978-0077361358. Simpson, John A.; Weiner, Edmung (1989). The Oxford English Dictionary. Oxford: Clarendon Press. ISBN 9780198611868. Sompayrac L (2019). How the immune system works. Hoboken, NJ: Wiley-Blackwell.
== Protein structure == The first structure of a creatine kinase solved by X-ray protein crystallography was that of the octameric, sarcomeric muscle-type mitochondrial CK (s-mtCK) in 1996., followed by the structure of ubiquitous mitochondrial CK (u-mtCK) in 2000. The atomic structure of the banana-shaped, dimeric cytosolic brain-type BB-CK was solved in 1999 at a resolution of 1,4 Å. Cytosolic BB-CK, as well as muscle-type MM-CK both form banana-shaped symmetric dimers, with one catalytic active site in each subunit.
Subsequent discussions led to Balfour's request, on 19 June, that Rothschild and Chaim Weizmann draft a public declaration. Further drafts were discussed by the British Cabinet during September and October, with input from Zionist and anti-Zionist Jews but with no representation from the large local Arab population in Palestine. By late 1917, the wider war had reached a stalemate, with two of Britain's allies not fully engaged: the United States had yet to suffer a casualty, and the Russians were in the midst of a revolution. A stalemate in southern Palestine was broken by the Battle of Beersheba on 31 October 1917. The release of the final declaration was authorised on 31 October; the preceding Cabinet discussion had referred to perceived propaganda benefits amongst the worldwide Jewish community for the Allied war effort. The opening words of the declaration represented the first public expression of support for Zionism by a major political power. The term "national home" had no precedent in international law, and was intentionally vague as to whether a Jewish state was contemplated. The intended boundaries of Palestine were not specified. The British government later confirmed that the words "in Palestine" meant that the Jewish national home was not intended to cover all of Palestine. The second half of the declaration was added to satisfy opponents of the policy, who had claimed that it would otherwise prejudice the position of the local population of Palestine and encourage antisemitism worldwide by "stamping the Jews as strangers in their native lands".
Sources: en.wikipedia.org
The MNPs may puncture the skin surface, enabling rapid onset of drug bypassing directly into the dermal capillaries. Pain-free. Can be localized to provide direct access to the intended tissues. Less dependent on skilled medical workers, as MNPs can be administered safely by the patient themself. Some drugs have poor solubility in water, with MNPs insoluble drugs and compounds can be directly "injected" to the dermal layer. Further enhancing the transdermal delivery of insoluble drugs. Better safety compared to needle and syringe method (needlestick). Less waste, eliminate pathogen transmission, and injuries. At least 300,000 needlestick related injuries occurred in the US annually, with disposal contributing to almost half of the injuries.
Its main constituents are (1) reaction scheme, (2) target of project & deliverables (product, quantity, required dates, specifications), (3) list of analytical methods, (4) process development opportunities (stepwise assessment), (5) list of required reports, (6) Safety, Health and Environment (SHE) issues, (7) materials to be supplied by customer and (8) packaging & shipping information. The technical part of a project usually determines its duration. Depending on the quality of the information contained in the "technology package" received from the customer and the complexity of the project as such, particularly the number of steps that have to be performed, it can be anywhere from 12 to 24 months. Depending on the amount of research involved, the total budget easily amounts to several million US dollars.
Mithridates' father was assassinated by poisoning, according to some at his mother's orders. After this, Mithridates's mother held regency over Pontus until a male heir was of age. Mithridates was in competition with another brother, whom his mother favored, for the throne. Supposedly during his youth he began to suspect plots against him at his mother's orders and was aware of her likely connection with his father's death. He then, supposedly, began to notice pains during his meals, and suspected his mother had ordered small amounts of poison to be added to his food in order to cause his health to deteriorate while avoiding notice of intent to kill him slowly. After other assassination attempts, he fled into the wilderness. While in the wild it is said that he began consuming non-lethal levels of poisons and mixing many into a remedy to make him immune to many poisons. In keeping with most medical practices of his era, Mithridates' anti-poison routines included a religious component supervised by Agari, or Scythian shamans who never left his side.
Sources: en.wikipedia.org
=== Box office === In North America, Stone Cold opened on 1729 screens through TriStar Pictures on May 17, 1991. It debuted in fifth place, drawing $2.8 million in its first weekend, and quickly fell off the charts, ending its run with a disappointing $9.2 million at the domestic box office. In the U.K., the movie was also distributed by Columbia TriStar and opened on June 19, 1992, only reaching eighth place. It perhaps fared best in Germany, where it was a minor success for independent distributor Ascot Elite, drawing 781,000 admissions in a medium-wide release and spending four weeks in the nation's top ten.
== Further reading == Wainwright, Dylan K.; Lauder, George V. (2017). "Mucus Matters: The Slippery and Complex Surfaces of Fish" (PDF). In Gorb, Stanislav N.; Gorb, Elena V. (eds.). Functional Surfaces in Biology III: Diversity of the Physical Phenomena. Biologically-Inspired Systems. Vol. 10. Springer, Cham. pp. 223–246. doi:10.1007/978-3-319-74144-4_10. ISBN 978-3-319-74144-4. Retrieved 2021-09-13.
Alpha cells (α-cells) are endocrine cells that are found in the Islets of Langerhans in the pancreas. Alpha cells secrete the peptide hormone glucagon in order to increase glucose levels in the blood stream.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.